Management Files First Quarter 2016 Financials

San Diego, CA -- (ReleaseWire) -- 05/20/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases is pleased to provide a shareholder update for First Quarter 2016.

"Innovus is a Company with multiple areas of expansion, progress and growth. As a result of our FlutiCare™ ANDA under review by the FDA, our increasing revenues,our continuous product acquisition, our entry into new markets and the planned uplist to the NYSE-MKT, first quarter 2016has been a high growth quarter for the Company.Investors are starting to realize the value of our products, business strategy and growth plans", said Dr. Damaj President & CEO of the Company. "Our execution of our business plan is meticulous, concise and it is working" continued Dr. Damaj.

Below are some of accomplishments of the First Quarter of 2016:

- Strong Financial position as we continue with no Going Concern

- This is testimony of our strong financial position and will help us with the NYSE review of our application for our planned uplisting

- 15% Increase in Revenues.

- Revenues increased from $196K to over $225K an increase of ~15%. This increase does not include significant revenue from the Beyond Human acquisition which we closed during March. During subsequent quarters, we will be able to include a full three months of revenue from this acquisition. 

- Over 6% Increase in Net Assets.

- Net assets increased from ~$6.3M to over $6.7M

- 50% Decrease in Net Loss per Share.

- Net loss per share decreased from $0.04 to $0.02 per share

- Initiated Discussions with NYSE-MKT for the planned listing.

- The Company initiated discussions with the NYSE for its planned listing and the requirements needed before filing its application

- Continue Launch Preparations for FlutiCare™ if approved by the FDA.

- The Company is continuing its launch preparation for Fluticare™ if approved by the FDA and those include but not limited to:

- Adding more distribution channels

- Negotiating multiple non-exclusive co-marketing agreements in the US to extend the availability of the product

- With potential approval the product isanticipated to be commercially available during early 2017

"With the potential approval of FlutiCare™ approaching, our revenues growing on a monthly from the Beyond Human products, and our market cap appreciating by the day, our goal of uplisting to the NYSE-MKT is becoming a reality.  Our goal is to achieve this listing on that exchange during 2016",continued Dr. Damaj

The Company will have a shareholder update call on:

When: Wednesday, May 25, 2016   4:05 EDT/1:05 PST

Length: ~ 15 minute presentation followed by a Question and Answer session

Dial in number: 530-881-1212

Meeting ID: 615-253-385#

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company

Contact:
Brokers and Analysts
Kevin Holmes Chesapeake Group
410-825-3930 info@chesapeakegp.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company Awaits a Potential FDA Approval for a Mega Drug

San Diego, CA -- (ReleaseWire) -- 05/11/2016 -- Most micro- and small-cap biotechnology firms are development-stage opportunities with a lengthy commercialization timeline. For investors, these companies have relatively high risks due to the high costs and uncertainty of regulatory approval.

Innovus Pharmaceuticals Inc. (OTCQB:INNV) is a rare exception to the rule. With 13 commercial products already on the market, the company has been generating sales from its products for two consecutive years. The company has ten signed commercial partnerships that could open the door to $500 million in potential sales milestones plus royalties in 60 countries – a move that could make 2016 a year of record growth. In addition, the Company is awaiting approval for its FlutiCare OTC drug (a GlaxoSmithKline Flonase competitor) for allergic rhinitis, a market that exceeds 1 billion dollars.

In this article, we'll take a closer look at Innovus Pharma and why investors may want to take a closer look at the stock as part of a diversified portfolio.

Targeting Large Markets
Innovus Pharma operates in three major end markets that generate more than $3 billion in combined annual sales.

The company's largest target market is allergic and non-allergic rhinitis – better known as "hay fever" or "stuffy nose" by the general public. The company's FlutiCare™ active is the #1 nasal steroid prescribed by physicians and used by patients. After dispensing more than 177 million units since 2007, Innovus is seeking to secure an Abbreviated New Drug Application from the FDA to launch an over-the-counter option for those seeking relief from rhinitis symptoms. According to a report by Fierce Pharma, GSK's Flonase OTC sold over $100,000M in a short period of time from its launch confirming the size of the market and the potential of FlutiCare™ if approved.

Click here to watch a recent CEOLive.TV interview with Innovus Pharmaceuticals CEO Dr. Bassam Damaj.

Female sexual dysfunction is the second market. The condition affects approximately 43% of women, compared to just 31% of men reporting similar difficulties. Whereas erectile dysfunction has become a $6 billion market, INNV's Zestra® is the only clinically proven, commercially sold consumer care product with statistical significance in addressing these issues for women. The company has sold more than 12.5 million doses sold to date.

Figure 1 – Zestra® Study Results – Source: Innovus Pharma
Click here to view the chart

Premature ejaculation, Innovus' third target area, affects nearly a third of men with few solutions on the market that effectively address the problem. The company's EjectDelay® over-the-counter gel has demonstrated improved intra-vaginal ejaculation latency time by 6.4 minutes compared to placebo treatments. Notably, this is significantly better than other drugs on the market, including Dapoxetine and Tempe, which have less than a five minute improvement.

Figure 2 – EjectDelay Study Results – Source: Innovus Pharma
Click here to view the chart

Expanding Revenue Potential
Innovus Pharma has significantly expanded its revenue potential moving into 2016 after signing new distribution deals and making a strategic acquisition.

As of early 2016, the company signed a total of ten commercial partnership deals with over $500 million in potential sales milestones plus royalties in 60 countries. The company already has significant distribution in the United States through Walmart, Target, Walgreen's Drugstore.com, and numerous other retailers, but these new distribution agreements will help expand international sales and develop a key pathway for future revenue growth.

The company also acquired Beyond Human assets in March of 2016, which had revenues of $1.3 million in 2013 and $2.2 million in 2014. With the new acquisition under its belt, the company adds a natural Testosterone booster and a natural Human Growth Agent to its product portfolio. The acquisition should also be accretive over the near-term since the private company generated some $400,000 in net profits in 2015 – up from $300,000 the year prior.

Finally, the company has been actively expanding the potential of its existing products by moving them from prescription products into the mass market. These efforts could significantly expand its overall market and improve revenues over the long-term. Management also plans to launch these OTC products into international markets in order to further expand sales.

Improving Financial Condition
Innovus Pharma recently raised $2.5 million in growth capital and repaid all of its outstanding debt, which puts the company on solid financial footing. In 2016, the company plans to become cash flow positive, and in 2017, it plans to become profitable on its income statement. These developments could set the stage for significant shareholder value creation as the company generates cash that can be reinvested in growth or distributed to shareholders.

In order to expand liquidity, the company plans to up-list to the NYSE MKT by the end of the year. The move could open the door to greater institutional investment, since many mutual funds and other institutions are forbidden from investing in stocks trading over-the-counter.

On April 19, SeeThruEquity issued a buy rating and $0.80 per share price target on the company. The analyst firm views the company as a high risk, high reward investment opportunity in the OTC pharmaceuticals space with a differentiated business model focused on men and women's health and vitality, and an expanding international presence. With a current share price of less than $0.10, the price target reflects a potential 8x profit.

Potential Catalysts Ahead
Innovus Pharma has numerous upcoming catalysts that may warrant a closer look by potential investors. With its new agreements in place, the company could see significant sales expansion throughout 2016 and into 2017. An up-listing to the NYSE MKT could expand its investor reach at the same time and build liquidity into the stock. At least one analyst believes that this could lead to a significant increase in share price over the next year.

Investors in the over-the-counter pharmaceutical or generics space, including small-cap companies like Juniper Pharmaceuticals Inc., Aclaris Therapeutics Inc., or Teligent Inc., may want to take a closer look at the stock.

For more information, visit the company's website at http://www.innovuspharma.com.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to:
http://www.innovuspharma.com
http://www.zestra.com
http://www.ejectdelay.com
http://www.myvesele.com
http://www.sensumplus.com
http://www.myandroferti.com
http://www.beyondhumantestosterone.com
http://www.getbeyondhuman.com
http://www.trybeyondhuman.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company

Contact:
Reuven Rubinson
Vice President of Finance
rreubinson@innovuspharma.com
858-964-5123

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 04/19/2016 -- SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Innovus Pharmaceuticals, Inc. (OTCBB:INNV)

The note is available here: INNV April 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

- Innovus Pharmaceuticals, Inc. (OTCBB:INNV, "Innovus") is an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality. 2015 was the second year of revenue generation for Innovus, and the company has recently made several strategic moves that should drive growth for the company in 2016E and beyond.

Key developments at the company include the following:

- In March, Innovus completed the acquisition of revenue generating assets of Beyond Human, which includes a growing commercial franchise that promises to triple Innovus if management executes.

- Innovus continues to expand its commercial products– now with 13 commercialized products and eight commercial agreements covering 60 countries.

- Innovus recently completed an important capital raise of nearly $2.5mn and has publicly stated its intention to uplist shares to the NYSE MKT.

Highlights of note are as follows:

Acquisition of Beyond Human to drive growth in 2016
Innovus completed what appears to be a well-conceived and potentially transformative strategic move on March 1, 2016 with the acquisition of revenue generating assets of Beyond Human. The move will add scale and accelerate the company's push towards achieving profitability – potentially as soon as 2017, if the company performs as hoped by management. Beyond Human was a profitable and growing company in 2015, with sales of $2.2mn and net profit of $0.4mn. Combined, management expects the company to achieve $4mn in pro forma revenues for 2016, with the company reaching cash flow neutral performance by the end of the year and profitability in 2017E.

Beyond Human adds synergy to slate of commercial products
With the acquisition of assets of Beyond Human, Innovus now has 13 commercial products and 3 pipeline products targeting a $3 billion market opportunity in men's and women's health and vitality and respiratory disease. Indeed we see the acquisition as having clear revenue synergies in men's health and vitality, given that Beyond Human's leading products are in the testosterone and human growth hormone markets – the testosterone market alone is expected to reach $3.8 billion by 2018E, according to Bloomberg and Statista. Beyond Human's natural Testosterone Booster supplement, Beyond T Human®, and its natural Human Growth Agent HGA®. These are both growing commercial products with customers and an online lead generation platform that is likely to overlap with products already offered by Innovus, such as EjectDelay®, Sensum+, and Vesele®.

Innovus price target of $0.80
We see Innovus as a high-risk / high-reward investment opportunity in the OTC pharmaceuticals space with a differentiated business model focused on men and women's health and vitality, and an expanding international presence. Our price target moves to $0.80. The change in target reflects the higher than expected share count relative to our initial valuation of the company in 2014 (67.6mn share now versus 24mn at initiation). We are enthused by the growth and synergies enabled by the Beyond Human acquisition, and eager to learn of the upcoming FDA decision for FlutiCare™. If achieved, the price target of $0.80 reflects potential upside of 400% from the recent price of $0.16.

Please review important disclosures at http://www.seethruequity.com.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit http://www.seethruequity.com.

To read over the source of the press release please click here.

Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm